翔宇SUNHOVER品牌怎么样 申请店铺

我要投票 翔宇SUNHOVER在滋补食材药材行业中的票数:564 更新时间:2026-01-23
翔宇SUNHOVER是哪个国家的品牌?「翔宇SUNHOVER」是 翔宇药业股份有限公司 旗下著名品牌。该品牌发源于山东省临沂市,由创始人林董在1999年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力翔宇SUNHOVER品牌出海!将品牌入驻外推网,定制翔宇SUNHOVER品牌推广信息,可以显著提高翔宇SUNHOVER产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

翔宇SUNHOVER怎么样

翔宇药业股份有限公司,山东省著名商标,孕产妇儿童补血知名品牌,高新技术企业,大型现代化民营制药企业


翔宇药业股份有限公司是翔宇集团控股上市公司,下辖一家全资子公司(山东仁和堂药业有限公司)和一家控股公司(山东诺维尔斯医药科技有限公司两家子公司)。拥有中药健康园、仁和堂化药园两大生产基地。生产妇科、儿科、精神、补益、心脑血管等11类制剂及原料药138个品种300多个品规。具有自主知识产权、自主定价权、国家中药保护品种及进入国家医保、基药、新农合目录的药品200多个。

翔宇药业坚持“打造中国妇幼用药一线药企”的企业发展战略,目前已经与3000多个经销商、100000多家医疗药店终端展开合作,销售网络遍布全国,部分产品远销欧美,为越来越多的家庭提供专业、优质的产品和服务!

化药盐酸地芬尼多取得美国DMF注册,盐酸米安色林、乳酸氟罗沙星原料药为国内独家产品替代进口,产品销往日本、墨西哥、美国等多个国家和地区。

翔宇药业严格按照新版GMP的要求设计,实施高标准GMP生产体系和质量体系,执行高于国标的内控标准。近年来,先后投入3.5亿元升级改造生产系统、生态处理系统。新建多功能提取车间及综合固体制剂车间,引进自动化控制系统、国际先进的药品检测设备,确保产品质量的稳定和优良。


Xiangyu Pharmaceutical Co., Ltd., a famous trademark of Shandong Province, a well-known brand of maternal and child blood supplement, a high-tech enterprise, and a large modern private pharmaceutical enterprise, Xiangyu Pharmaceutical Co., Ltd. is a listed company controlled by Xiangyu Group, which has a wholly-owned subsidiary (Shandong Renhetang Pharmaceutical Co., Ltd.) and a holding company (Shandong novels Pharmaceutical Technology Co., Ltd.) Subsidiaries). There are two production bases of Chinese medicine health park and Renhetang pharmaceutical park. More than 300 specifications of 138 varieties of 11 kinds of preparations and APIs, including Gynecology, pediatrics, spirit, tonic, cardio cerebrovascular and so on, are produced. There are more than 200 drugs with independent intellectual property rights, independent pricing rights, national protected varieties of traditional Chinese medicine and entering the national medical insurance, basic medicine and new rural cooperative medical insurance catalogue. Xiangyu pharmaceutical adheres to the enterprise development strategy of "building a first-line pharmaceutical enterprise of Chinese maternal and child medicine". At present, it has cooperated with more than 3000 distributors and 100000 Medical Pharmacy terminals. Its sales network spreads all over the country, and some products are exported to Europe and America, providing more and more families with professional and high-quality products and services! Difenidol hydrochloride, a chemical drug, has been registered with DMF in the United States. The raw materials of mianserin hydrochloride and fleroxacin lactate are the exclusive products in China, which are sold to Japan, Mexico, the United States and other countries and regions. Xiangyu pharmaceutical has designed in strict accordance with the requirements of the new GMP, implemented a high standard GMP production system and quality system, and implemented internal control standards higher than the national standard. In recent years, 350 million yuan has been invested in upgrading production system and ecological treatment system. New multi-functional extraction workshop and comprehensive solid preparation workshop, introduction of automatic control system, international advanced drug testing equipment, to ensure the stability and excellence of product quality.

本文链接: https://brand.waitui.com/c76e2d7a6.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美股大型科技股盘前涨跌不一,Arm涨超2%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,Arm涨超2%,英伟达涨超1%,谷歌涨0.1%,微软涨0.06%;特斯拉跌0.17%,奈飞跌0.11%,亚马逊跌0.07%,苹果跌0.03%。

2小时前

热门中概股美股盘前涨跌互现,阿里巴巴跌超1%

36氪获悉,热门中概股美股盘前涨跌互现,截至发稿,阿里巴巴、京东跌超1%,小鹏汽车跌近1%,网易跌0.48%,蔚来跌0.21%;百度涨超1%,拼多多涨0.75%,理想汽车涨0.42%,B站涨0.09%。

2小时前

晶升股份:拟购买为准智能100%股份,交易作价8.57亿元

36氪获悉,晶升股份公告,公司拟通过发行股份及支付现金的方式购买本尚科技等10名交易对方持有的为准智能100%股份,同时募集配套资金。为准智能100%股份的交易作价为8.57亿元。本次交易构成关联交易和重大资产重组,但不构成重组上市。交易完成后,为准智能将成为上市公司控股子公司。

2小时前

天合光能:将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”

36氪获悉,天合光能公告,公司拟缩减“年产35GW直拉单晶项目”的募集资金投资金额,不再实施二期15GW项目,并将剩余募集资金17亿元用于新项目“分布式智慧光伏电站建设项目”。新项目预计2026年底建成并投入运营。公司表示,本次变更有利于提高募集资金使用效率,合理优化资源配置,巩固市场地位,不会对公司正常经营产生不利影响。该事项尚需提交公司股东会和债券持有人会议审议通过后方可实施。

2小时前

宝洁第二财季净销售额222亿美元,同比增长1%

当地时间1月22日,宝洁公司发布2026财年第二季度(2025年10-12月)财报。财报显示,第二财季净销售额为222亿美元,同比增长1%;摊薄后每股净收益为1.78美元,同比下降5%。该公司维持2026财年总销售额同比增长1%至5%的指引区间,将2026财年摊薄后每股净收益增长指引从原先的3%-9%调整至1%-6%。(界面)

2小时前

本页详细列出关于翔宇SUNHOVER的品牌信息,含品牌所属公司介绍,翔宇SUNHOVER所处行业的品牌地位及优势。
咨询